Adaptimmune Reports Q1 Financial Results and Provides Business Update

Adaptimmune Therapeutics (NASDAQ: ADAP) reported Q1 2025 financial results and business updates. TECELRA®, their first commercial product in the sarcoma franchise, achieved $4.0 million in net sales in Q1 2025, with the company providing full-year sales guidance of $35-$45 million. Launch metrics show strong momentum with 28 Authorized Treatment Centers available, 21 patients aphresed, and 14 doses invoiced. The company maintains a 100% manufacturing success rate with no payer denials. Their second product, lete-cel, is on track for rolling BLA submission in late 2025 with anticipated approval in 2026. Financial results show Total Liquidity of $60 million as of March 31, 2025, with Q1 revenue of $7.3 million. However, the company reported a net loss of $47.6 million and disclosed substantial doubt about their ability to continue as a going concern.